Stevanato Group Q3 revenue beats estimates on biopharma segment

Overview

• Italy drug containment and delivery firm's Q3 revenue grew 8%, beating analyst expectations

• Adjusted diluted EPS for Q3 rose 14% to €0.16

• Company maintained full-year 2026 guidance

Outlook

• Stevanato Group maintains 2026 revenue guidance of €1.260 bln to €1.280 bln

• Company expects 2026 adjusted EBITDA of €335.0 mln to €345.2 mln

• Company anticipates low single-digit revenue growth in 2027 due to lower GLP-1 volumes

Result Drivers

• BDS SEGMENT GROWTH - Organic revenue from Biopharmaceutical and Diagnostic Solutions rose 11%, driven by high-value and other containment and delivery solutions

• ENGINEERING SEGMENT DECLINE - Revenue from the Engineering Segment fell 12%, mainly due to lower pharma visual inspection and assembly and packaging sales

• GLP-1 REVENUE IMPACT - Lower GLP-1 therapy revenue was offset by over 30% growth in non-GLP-1 biologics demand, according to CEO Franco Stevanato

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Stevanato Group SpA is $25.00, about 26.6% above its November 2 closing price of $19.74

• The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 26 three months ago

Reuters Recommended Reads

• Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises

• Nov 3 - Biomérieux third-quarter organic sales growth beats expectations

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)